Frontline therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study

Mohty, Mohamad; Terpos, Evangelos; Mateos, M.V.; Palumbo, Antônio; Lejniece, Sandra; Beksaç, Meral; Bekadja, M.A.; Legieć, Wojciech; Dimopoulos, M. A.; Stankovic, Svetlana; Durán, María Soledad; Stefano, Valerio De; Kochkareva, Y.; Laane, Edward; Berthou, Christian; Salwender, Hans-Juergen; Masliak, Zvenyslava; nas, V. Pe eli; Willenbacher, Wolfgang; Silva, J.; Louw, Vernon; Nemet, Damir; Borbényi, Zita; Abadi, Uri; Pedersen, Robert S.; ernel, P.; Potamianou, Anna; Couturier, Catherine; Olie, Robert A.; Feys, Caroline; Thoret-Bauchet, Florence; Boccadoro, Mario

doi:10.1016/j.clml.2015.07.321

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of autologous transplantation (ASCT) remained more or less constant at ~ 35% of patients in the 1 st line setting over the whole period, comparing well to international practice patterns [ 13 ], while the use of 2 nd line ASCT increased from 5.5% to 18.7% of patients ( Table 2 ). The median age of this myeloma cohort was 63.86 +/- 11.82 years at first diagnosis thus roughly half of them would not qualify for an ASCT using a threshold of 65 years of age widely in use in Europe.…”

Section: Discussionmentioning

confidence: 89%

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics

Willenbacher

Weger²,

Rochau³

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

ObjectiveClinical trials demonstrate improving survival in patients with multiple myeloma (MM) after treatment. However, it is unclear whether increased survival translates to a similar benefit in a real world setting.MethodsWe analyzed the overall survival of 347 multiple myeloma patients in Austria by means of a national registry (AMR), focused on results from 3rd and later lines of therapy. This benchmark was chosen to define a baseline prior to the broad application of upcoming 2nd generation drugs (carfilzomib, pomalidomide).ResultsProjected 10 years survival for patients with MM in Austria is estimated to be 56% in patients diagnosed in between the years 2011–2014, 21% in patients with a diagnosis made between 2000–2005, and 39% in those with a diagnosis made between 2006–2010). For the same intervals a significant increase in the use of both bortezomib, lenalidomide and thalidomide—so called IMiDs (from 2005 onwards) and their simultaneous use in combination therapies (from 2010 onwards) could be shown. The use of autologous transplantation (ASCT) remained more or less constant at ~ 35% of patients in the 1st line setting over the whole period, comparing well to international practice patterns, while the use of 2nd line ASCT increased from 5.5% to 18.7% of patients. Patients in 3rd or later line treatment (n = 105), showed that even in relapsed and refractory disease median survival was 27 months with a considerable proportion of long-term survivors (~20%).Conclusion & PerspectiveWith the expected emergence of additional active anti-myeloma compounds, we aim to assess survival in patients with relapsed and refractory MM.

show abstract

Section: Discussionmentioning

confidence: 89%

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics

Willenbacher

Weger²,

Rochau³

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Considering the rapid evolution in the TE‐NDMM treatment landscape, the data published several years ago are not directly comparable to the most recent analyses like ours. In a prospective real‐world study conducted among patients from Europe, the Middle East, and Africa, the most common induction regimens for FL SCT between 2010 and 2012 were VTd (31.8%), Vd (18.7%), and VCd (16.4%), highlighting VTd as the SoC during these years 20 . Another more recent study assessing the evolution of MM induction regimens in Europe between 2014 and 2016 showed that the use of VT‐based regimens increased in France and Spain (from 18% to 32% and 8% to 15%, respectively) and remained stable in Italy (from 37% to 36%); no VT‐based regimens were used in Germany during these years, 11 corroborating our findings where VTd still appeared to be widely used in Italy and to a lesser extent in Spain and France but not in Germany.…”

Section: Discussionmentioning

confidence: 99%

Real‐world study on adoption of standard‐of‐care for transplant‐eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy

Weisel

Wadlund²,

Gungor³

et al. 2022

European J of Haematology

View full text Add to dashboard Cite

Objectives This non‐interventional observational study described the current standard‐of‐care for transplant‐eligible newly diagnosed multiple myeloma (TE‐NDMM) patients in France, Germany, Spain, and Italy, and recorded the evolution in regimen adoption in distinct elements of frontline treatment during 2017–2020/2021. Methods Clinical information on ongoing (I) or previous (II) TE‐NDMM patients was extracted from the Cancerology database. Proportions of patients receiving regimens in each element and the evolution in regimen adoption were determined for the entire population and each country. Results Most common induction regimens among I patients were VRd in France (75.3%) and Spain (44.1%), VTd in Italy (65.2%), and regimens other than VRd/VTd/VCd in Germany. Maintenance was ongoing/planned for 78.3%, 62.3%, 65.2%, and 61.4% patients in France, Germany, Spain, and Italy, respectively. Among II patients, VRd induction increased from 27.0% in 2017 to 65.7% in 2019 in France, remained relatively low in Spain and Germany, and not present in Italy. In Italy and Spain, VTd induction declined from 72.4% and 58.3% in 2017 to 52.8% and 17.3% in 2019, respectively. VCd induction in Germany declined from 85.2% in 2017 to 64.1% in 2019. Conclusion The use of bortezomib triplets in induction varied markedly over time and between selected countries.

show abstract

“…Although there are a greater number of studies on this group, and subsequently more observations in this study, these patients receive a wide variety of treatments. This is likely due to diversity in respective patient populations (as evidenced by the SCT rate ranging from 18.3% to 68.9%), with reported utility showing substantial variability (Acaster, Gaugris, Velikova, Yong, & Lloyd, ; Mohty et al, ). Conversely, patients receiving their second treatment class appear to exhibit less variability in reported health related quality of life.…”

Section: Discussionmentioning

confidence: 99%

“…Individual level data were made available by Janssen from the EMMOS registry and the APEX clinical study (Mohty et al, ; Richardson et al, ). The EMMOS registry contains data from 2,521 patients in 22 countries in Europe and Africa, across all classes of MM treatment.…”

Section: Methodsmentioning

confidence: 99%

Frequentist and Bayesian meta‐regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data

et al. 2019

View full text Add to dashboard Cite

This analysis presents the results of a systematic review for health state utilities in multiple myeloma, as well as analysis of over 9,000 observations taken from registry and trial data. The 27 values identified from 13 papers are then synthesised in a frequentist nonparametric bootstrap model and a Bayesian meta‐regression. Results were similar between the frequentist and Bayesian models with low utility on disease diagnosis (approximately 0.55), raising to approximately 0.65 on first line treatment and declining slightly with each subsequent line. Stem cell transplant was also found to be a significant predictor of health‐related quality of life in both individual patient data and meta‐regression, with an increased utility of approximately 0.06 across different models. The work presented demonstrates the feasibility of Bayesian methods for utility meta‐regression, whilst also presenting an internally consistent set of data from the analysis of registry data. To facilitate easy updating of the data and model, data extraction tables and model code are provided as Data S1. The main limitations of the model relate to the low number of studies available, particularly in highly pretreated patients.

show abstract

Frontline therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study

Cited by 4 publications

References 0 publications

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics

Real‐world study on adoption of standard‐of‐care for transplant‐eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy

Frequentist and Bayesian meta‐regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data

Contact Info

Product

Resources

About